Ischemia Peripheral Arterial Disease Stent 
Med Page Today
APRIL 29, 2024
(MedPage Today) -- The FDA approved the Esprit BTK everolimus-eluting scaffold system for chronic limb-threatening ischemia (CLTI) below the knee, Abbott announced on Monday. This system represents the first drug-eluting resorbable scaffold with.
Med Page Today
APRIL 30, 2024
(MedPage Today) -- For patients with peripheral artery disease (PAD) and chronic limb-threatening ischemia, drug-eluting stents and drug-coated balloons did not improve amputation-free survival compared with balloon angioplasty alone in the BASIL.
DAIC
FEBRUARY 14, 2024
The Efemoral Vascular Scaffold System (EVSS) offers a new approach to treating peripheral arterial occlusive disease (PAOD) by addressing the specific anatomic challenges and complex biomechanics of patients with athero-occlusive disease in the leg. The global burden of peripheral artery disease.
DAIC
MAY 30, 2024
The prospective, international, multicenter single-arm observational study evaluated the treatment of de novo, restenotic or occluded iliac lesions in 160 patients with Rutherford Class 2-6 peripheral artery disease using the Dynetic-35 cobalt chromium balloon-expandable stent system. At baseline, 12.5% Brodmann M.
DAIC
MARCH 20, 2024
The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. 2,3 It has shown 99.6%
Dr. Anish Koka
MAY 16, 2023
years of age, P <0.001), cerebral or peripheral artery disease (6.2% While cardiologists have always recognized the presence of disease in the smaller arteries (microvascular disease), the presence of significant microvascular disease in the absence of epicardial disease is thought to be fairly rare.
Expert insights. Personalized for you.
111 
Let's personalize your content